vimarsana.com

Page 4 - ஸ்காட்ஸ்டேல் ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DEA Finally Ready To End Federal Marijuana Research Monopoly, Agency Notifies Grower Applicants

DEA Moves Toward Approving More Research Marijuana Growers

Some 36 states now permit marijuana to be used medically, and 17 allow recreational use. Yet researchers who wish to study the drug’s health effects have been limited since 1968 to a single legal supplier of the drug, the University of Mississippi. That looks set to change soon, as the US Drug Enforcement Administration (DEA) announced Friday (May 14) that it has sent memorandums of agreement (MOAs) to hopeful growers “outlining the means by which the applicant and DEA will work together to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations.”  “We were euphoric. This is a victory for scientific freedom. It’s finally a chance to use real-world cannabis in our own studies and supply genetically diverse cannabis to scientists across the nation,” says Sue Sisley, the president and principal investigator at the Scottsdale Research Institute (SRI), tells

DEA Takes Steps Toward Letting Companies Produce Marijuana for Research Purposes

Agriculture your username 2 days ago The Drug Enforcement Administration (DEA) notified companies recently that they are moving toward approving applications to grant federal authorization for manufacturing marijuana for research purposes, according to an article from Marijuana Moment.  The article explained that over the last 50 years, only one facility has held this level of approval – the University of Mississippi. The Obama administration initially opened applications for additional companies to gain authorization to produce marijuana, but the Biden administration was the first to make explicit progress towards approval. These recent advancements by the DEA are the first look into the Biden administration’s stance on cannabis policy.

U S set to allow more facilities to produce marijuana for research

U S set to allow more facilities to produce marijuana for research
sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain QIXLEEF has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the acceleration of a revolutionary Phase 2 clinical trial, PLENITUDE©, to evaluate the safety and efficacy of the investigational cannabis medicine, QIXLEEF, for use in managing uncontrolled pain in patients with advanced cancer. QIXLEEF is the Company s inhaled proprietary drug formulation which has a fixed ratio of THC and CBD. The medication is inhaled through a Class II medical vaporizer. When pharmaceutical grade cannabis is vaporized rather than smoked, the beneficial components can be inhaled without the generation of smoke and combusted by-products.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.